Since insufficient CD8 T cells and tumor immunogenicity in the TME are common causes of the limited efficacy of anti-PD-1 antibodies, these results suggest the potential of Q702 as a promising agent when combined with anti-PD-1 antibody therapy to overcome this limitation. Here, CD8A is linked to neoplasm.